M&T Bank Corp Boosts Stock Holdings in LeMaitre Vascular, Inc. $LMAT

M&T Bank Corp lifted its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2,240.5% during the fourth quarter, Holdings Channel reports. The fund owned 398,069 shares of the medical instruments supplier’s stock after acquiring an additional 381,061 shares during the period. M&T Bank Corp’s holdings in LeMaitre Vascular were worth $32,283,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Cornerstone Planning Group LLC increased its position in shares of LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 283 shares during the period. MAI Capital Management purchased a new stake in shares of LeMaitre Vascular during the third quarter worth $38,000. First Horizon Corp purchased a new stake in shares of LeMaitre Vascular during the third quarter worth $39,000. Geneos Wealth Management Inc. increased its position in shares of LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares during the period. Finally, EverSource Wealth Advisors LLC purchased a new stake in shares of LeMaitre Vascular during the second quarter worth $47,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $112.80 on Thursday. LeMaitre Vascular, Inc. has a fifty-two week low of $78.01 and a fifty-two week high of $118.01. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of 44.94, a price-to-earnings-growth ratio of 3.22 and a beta of 0.67. The firm has a 50-day simple moving average of $106.17 and a 200-day simple moving average of $92.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The business had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. During the same quarter in the prior year, the firm earned $0.49 earnings per share. The business’s quarterly revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular’s payout ratio is currently 39.84%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LMAT shares. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. Weiss Ratings upgraded shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, March 10th. Barrington Research boosted their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Wells Fargo & Company boosted their target price on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.80.

Insider Transactions at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 1,044 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the transaction, the insider directly owned 6,677 shares of the company’s stock, valued at $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 55,930 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the completion of the sale, the chief executive officer owned 1,476,500 shares of the company’s stock, valued at approximately $159,181,465. The trade was a 3.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 215,438 shares of company stock worth $23,062,911. Company insiders own 9.50% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.